Spots Global Cancer Trial Database for An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
Official Title: An Extension Study of T-1101 (Tosylate) Administered Orally to Patients With Advanced Refractory Solid Tumors
Study ID: NCT03349073
Conditions
Interventions
Study Description
Brief Summary: T-1101 is a novel anti-cancer agent being developed by Taivex Therapeutics Corporation, and is being studied in a phase I dose escalation trial, protocol TAI-001. That trial's primary aim is to study the safety and tolerability of T-1101 (Tosylate) in subjects with advanced refractory solid tumors, and provides for a maximum of 2 cycles of treatment. At the end of 2 cycles of treatment, it is likely that some patients will be continuing to receive clinical benefit from T-1101 (Tosylate). The intention of this program is to enable these patients to continue to receive T-1101 (Tosylate) at the discretion of the principal investigators and Taivex Therapeutics Corporation.
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
China Medical University Hospital, Taichung City, , Taiwan
National Cheng Kung University (NCKU) Hospital, Tainan, , Taiwan
Taipei Medical University Hospital, Taipei, , Taiwan
National Taiwan University Hospital, Taipei, , Taiwan
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
